IRLAB Therapeutics Competitors and Similar CompaniesClear all

IRLAB Therapeutics's competitors and similar companies include Dizlin, Alembic Pharmaceuticals and UCB.

	IRLAB Therapeutics IRLAB Therapeutics is a biotechnology company focused on Parkinson's disease (PD).	Dizlin Dizlin Pharmaceuticals is a pharmaceutical research company developing treatments for Parkinson's disease.	Alembic Pharmaceuticals Alembic Pharmaceuticals is a company that develops, manufactures, and markets pharmaceutical products, pharmaceutical substances, and intermediates	UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
Founding Date	Founding Date 2013	Founding Date 2003	Founding Date 2010	Founding Date 1928
Type	Type Public	Type Private	Type Public	Type Public
Tags	Tags Healthcare biotech drug development pharma	Tags Healthcare clinical research drug development pharma	Tags Healthcare biotech drug development pharma	Tags Healthcare biotech drug development pharma
Locations	Locations Göteborg, SE HQ	Locations Göteborg, SE HQ	Locations Vadodara, IN HQ Baska, IN Mumbai, IN Namthang, IN Vadodara, IN Vadodara, IN	Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more
Employees	Employees 30	Employees 6	Employees 14,858	Employees 9,052
Valuation ($)	Valuation ($) 63.7 m	Valuation ($) N/A	Valuation ($) N/A	Valuation ($) 34.3 b
Financial
Revenue (est.)	Revenue (est.) kr57.5m (FY, 2025)	Revenue (est.) N/A	Revenue (est.) ₹73.4b (FY, 2026)	Revenue (est.) €7.4b (FY, 2025)
Cost of goods	Cost of goods N/A	Cost of goods N/A	Cost of goods ₹19.8b (FY, 2026)	Cost of goods €1.4b (FY, 2025)
Gross profit	Gross profit kr62.8m (FY, 2025)	Gross profit N/A	Gross profit ₹54.1b (FY, 2026)	Gross profit €7.2b (FY, 2025)
Net income	Net income (kr110m) (FY, 2025)	Net income N/A	Net income ₹6.7b (FY, 2026)	Net income €1.6b (FY, 2025)